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3. Summary   
3.1 Background 
Little was known on long term survival, the use of hospital days, symptoms both initially and 
terminally, and the quality of lung cancer care for the population of the patients with lung 
cancer in Haugalandet, Norway. 
3.2 Material and methods   
In a retrospective study we followed a cohort of all incident lung cancer patients from 
01.01.1990 to 31.12.1996 in the hospital area of Haugesund hospital (Haugalandet).  To study 
the predictors for long term survival we followed the patients either to death or to the last 
follow up to 31.12.2008. All hospital admissions and hospitalization days were recorded for 
all patients up to 01.12.2003. We studied the terminal symptoms in the last eight weeks of 
patients’ lives who died before that date. Finally, we compared for the same time period four 
quality indicators in the patient cohort from the local hospital-based lung cancer registry 
(LCR) with the patient cohort in the Cancer Registry of Norway (CRN) both from the same 
geographical area (Haugalandet), and a cohort of all lung cancer patients from the rest of 
Norway.   
3.3 Results 
A total of 271 patients were diagnosed with lung cancer in these seven years. The long term 
survival was poor, with one-year survival of 29.2% and five- and ten-year survival of 8.5% 
and 5.5%, respectively. The median (IQR) survival time was 5.7 (1.9,14.1) months. No 
weight loss, young age, limited stage, good performance status and surgical treatment were 
predictors for long survival, which were also not influenced by the diagnostic delay time. 
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Furthermore, we found that all 271 patients had a median number (inter quartile range, IQR) 
of 3 (2,5) admissions and 35 (18,58) hospitalization days. Those who did not survive spent 
19% of their remaining life time in institutions. Young age, limited disease and good 
performance status were associated with high number of hospital days, but these effects were 
not significant when adjusted for treatment.  
Information on symptoms in the terminal 8 weeks was obtained in 247 of the patients who 
died before 1st December 2003.  Pain was observed in 85%, psychological symptoms 
(anxiety, insomnia and/or depression) in 71%, dyspnea in 54%, neurologic symptoms in 28%, 
cough in 24%, nausea in 21%, and hemoptysis in 9%. Young age and small cell cancer 
(SCLC) were risk the factors for psychological symptoms, and initial stage III disease was a 
risk factor for terminal dyspnea. Terminal cough was associated with NSCLC and nausea 
with SCLC.  
The average minimal difference of clinical importance judged by 26 physicians for four lung 
cancer quality indicators (histological/cytological verification, staging, surgery and one year 
survival) varied from 18% to 23% from the national average of the indicators.  
The level of the four quality indicators studied was in agreement with the patient cohort from 
Haugalandet and the cohort from the rest of Norway. However, the sample sizes necessary to 
detect a 20% difference from the national average (power 0.80, p<0.05) varied from 435 to 
2826 cases depending on the prevalence of the indicators.  
 
3.4 Conclusions 
The long term survival of lung cancer is poor, with only less than 10% of the patients 
surviving after five years. The patients who died spent one fifth of their remaining time after 
9 
 
diagnosis in health care institutions. Those with limited disease and young age had most days 
in the hospital. All patients had one or more symptoms requiring treatment in the terminal 
stage of the disease, and pain was the most frequent symptom in 85% of the patients.  The 
quality of lung cancer care is difficult to evaluate in small management units. The small 
decentralized units should thus be merged to larger cooperative units with standardized 
routines. A national quality registry on lung cancer would then be a powerful tool contributing 
to improved quality of local lung cancer care. 
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8. Introduction 
8.1 Incidence, mortality and survival of lung cancer  
Until 1990 no data were published on lung cancer from an entire population in defined 
hospital areas in Norway. The hospital area belonging to Haugesund hospital, Haugalandet, 
consists of municipalities both from Rogaland and Hordaland county. In these two counties 
there was a steady increase in the incidence of lung cancer from the start of registration in the 
Cancer Registry of Norway (CRN) until the present study (1) (figure 1 and figure 2). 
Figure 1 Age adjusted incidence rate of lung cancer in trachea, bronchus and lung per 100 000 in 
Rogaland county 1956 – 1995 
   
 
Figure 2 Age adjusted incidence rate of lung cancer in trachea, bronchus and lung per 100 000 in 
Hordaland county 1956 – 1995 
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Within Norway (2) there are marked differences in the incidence between the counties (3), as 
it was at the time of this study (figure 3), but there is no valid explanation for this (1), 
therefore it will be discussed in chapter 12.1.4. 
Figure 3 Incidence of lung cancer in Norwegian counties 1990 – 95 
 
The mortality rate in lung cancer among  men in Norway has reached a plateau (4, 5) while 
the incidence in women continues to increase (figure 4)(6).   
Figure 4 Trends in incidence and mortality rates and 5-year relative survival proportions in lung cancer 
in Norway (ICD-10, C33-34, from Cancer Registry of Norway, 2008) 
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Thus, the lung cancer incidence between young males and females in Norway in from the 
years 1954 – 1998 was converging the last 20 years of this period (figure 5) (6). 
Figure 5 Sex specific incidence fraction of lung cancer in Norway from 1988 – 2007 (Sagerup et al 
2011) 
 
 
Globally, 1.35 millions new patients were estimated to be diagnosed with lung cancer in 2002, 
which is the most frequent cause of cancer death  (7). In developed countries the incidence is 
declining in males (7-10) while there is a lower but increasing incidence in women (11-14). 
There are great differences in the incidence of lung cancer among the countries (11, 15).  
Squamous cell carcinoma was previously the most frequent histological subtype, but there has 
been a shift to adenocarcinoma as the most prominent subtype in Norway (6). This is also in 
agreement with the findings in a Sweden (13), Finland (16) and the U.S. A.  (8). No data were 
available for the Haugesund hospital area for the incidence and mortality of lung cancer by 
sex, age, stage, histology and performance status. 
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8.2 Etiology of lung cancer 
8.2.1 Tobacco smoking.  
A connection between tobacco smoking and lung cancer was found early in Norwegian 
studies  (17), and  was later well established (18). A dose-response relation between tobacco 
consumption and lung cancer is found in most studies (4, 19, 20). In Northern Sweden, an 
increase in the smoking prevalence was followed by an increase in lung cancer mortality (21). 
Smoking was strongly associated with lung cancer risk in a large prospective American study 
(22). Among 219  Norwegian lung cancer patients referred to a central hospital only six (3%) 
were non-smokers (23). This strong association between tobacco smoking and lung cancer 
may explain that the incidence of lung cancer in men is declining following a decrease in 
tobacco smoking (7-10). There is an increasing incidence of lung cancer in women following 
the increased use of cigarettes in females (6, 11).  
8.2.2 Other risk factors.  
Passive smoking represents a risk factor for lung cancer according to evidence found in 
studies of non-smoking women exposed to passive smoking from their spouses (8, 24). 
Adenocarcinoma in a woman’s lung exposed to passive smoking was recognized as an 
occupational disease (25). The risk for lung cancer was associated with passive smoking at 
their homes in Japanese non-smoking women, and if they were exposed to additionally 
passive smoking at the workplace (26).    
Occupation exposures are known to be important etiological factors for lung cancer, and it is 
the most known work-related cancer (27). In a national cohort study from Norway on 53 
occupational groups after adjusting for active smoking, an excessive risk of lung cancer was 
found in 26 groups, and  20%  were considered to be related to exposure of asbest, polycyclic 
aromatic hydrocarbons, arsenics, certain metal compounds and radon (28). The population 
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etiological fraction attributed to occupation was estimated to 9%  in a case-control study from 
Sweden (29). Two recent case-control studies from the New-Zealand and Italy found 
increased risk of lung cancer associated both with current and past occupational exposures 
(30, 31).  
Radon exposure is known for a long time as a risk factor for lung cancer both as occupational 
risk (32, 33) and as a risk factor due to domestic exposure (34). In a study of indoor radon 
exposure in 427 municipalities in Norway the incidence of small-cell anaplastic lung cancer 
(SCLC) increased with increasing radon exposure  (35). However, measurements of radon 
concentrations showed great variations between counties, and municipalities, as well as 
between houses within the municipalities (36). The counties Hedmark and Oppland with the 
highest radon measurements were among those with the lowest lung cancer incidence (figure 
3), and Aust-Agder with the highest lung cancer incidence had low radon measurements.  
Socioeconomic factors have been studied in a meta-analysis. A low level of education, low 
income and socioeconomic occupation were associated with increased risk for lung cancer, 
after adjusting for tobacco smoking (37). In a Danish study the incidence rate of lung cancer 
has increased with social disadvantages as  poor employment status, being unmarried, 
urbanization and the presence of somatic or psychiatric diseases (38). In two studies of 
European countries a higher lung cancer mortality rate in men was found in the groups with 
low educational level compared to those with high education. However, in women in 
Southern Europe low lung cancer mortality was associated with low educational level (39, 
40).  The question is always how well these studies have adjusted for tobacco smoking. Both 
studies suggest that differences in prevalence and intensity of smoking contribute to variations 
in the lung cancer mortality.  
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8.3 Predictors of long term survival in lung cancer 
In 1981-85 a five year overall survival of lung cancer in Norway was 8.5% for men and 8.1% 
for women, according to CRN. In 1986-90, the corresponding percentages were 8.6% and 
10.0%, respectively (41). Age and anatomical stage were prognostic factors for survival. In 
West Sweden, the 5-year survival rate was 8.3% in 1976-85 (42).  In a population-based study 
of all incident lung cancer patients in Scotland in 1995 the 3 year survival was 7%, and 
predictors for survival were localized disease, active treatment within 6 months after 
diagnosis, young age, and involvement of a lung cancer specialist (43). In lung cancer patients 
diagnosed in USA between 1995 and 1998  Tammemagi found that adverse symptoms such 
as  weight loss, fatigue, neurological symptoms and extensive stage were negative predictive 
factors for survival (44). The influence of delay time from symptom onset to diagnosis on 
survival was examined in lung cancer in patients from 1987-89 in Spain. Surprisingly, a long 
delay time was associated with better survival (45). This conflicting evidence for predictors of 
long term survival was of importance for the lung cancer population of Haugalandet.   
8.4 Hospital admissions and days in lung cancer care 
There are great variations in most studies of the use of resources in lung cancer patient 
populations depending on the items of costs which are included  (46). However, a common 
finding is that hospitalizations are a main cost driver (47-49) counting for 40 – 70% of the 
expenses in lung cancer. Some cost studies included only patients given chemotherapy (50), 
and other at certain stages of the disease (51).  
The resources used on all lung cancer patients were not available in a community which 
included admissions and hospital days in the whole course of the disease. Hospitalization 
(admissions and hospital days) was the major cost driver in a retrospective study on patients 
with SCLC referred to hospital from 1994-97 (52).  
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Lung cancer is a serious disease, and many patients are asking the physicians about the time 
necessary to stay in the hospital. Knowledge on such data was not available at the time of the 
study. 
8.5 Terminal symptoms in lung cancer 
Symptoms are the main causes for patients seeking health care services and physicians. 
Studies on terminals symptoms in all lung cancer patients were not available. In a study in 
England on patients with NSCLC recruited from chest clinics, 80% experienced cough, 60% 
chest pain, 90% dyspnea and 20% hemoptysis the last two months before death (53).  As 
much as 90% of  lung cancer patients referred to a palliative care service in Italy had pain 
(54). In the recent years most studies on the effect of various treatment options include quality 
of life (QOL) as one of the end-points (55-57). Methods used to get information on QOL are 
poorly applicable in terminal care, since many of the terminally ill patients are too sick to fill 
out the questionnaires (58). In a prospective population-based study on lung cancer in South-
Norway, about 40% of the patients did not answer the health related QOL-questionnaires (59) 
already at the time of the diagnosis. The patients not answering were older and had poorer 
performance status than those who answered. A usual exclusion criterion of patients with 
advanced lung cancer invited to multicenter studies is:  no ability to fill out the quality of life 
questionnaire. Knowledge on the prevalence and predictors of terminal symptoms is one 
prerequisite for good palliative care management.    
8.6 Quality of lung cancer care 
8.6.1 Quality indicators 
Lung cancer care is a complex disease, and there is no agreement how to measure quality 
(60).  In a study among the Nordic countries the aim was to do benchmarking on the quality 
of care both in lung cancer and other important diseases by using quality indicators. However, 
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the conclusion was that the differences between the countries in e.g. legislation and reporting 
data were so great that comparisons were impossible and that present modern health care 
systems were not able to report their quality (61).   
Quality indicators may be focused on firstly structure of care, e.g. which resources are 
available to do the diagnostic work and treatment, and secondly on process of care which 
refers to the treatment actually given to the patient (62), which is often based on guidelines. 
The third type is the outcome indicators, as 30 days survival after lung cancer surgery, or one 
year mortality (60, 63).  Much of the work with quality indicators in lung cancer care is done 
on surgically treated patients as in Denmark. Indicators are here used in a quality registry 
which seems to have contributed to an improvement in the quality of lung cancer surgery 
(64). Such registries for lung cancer are also in use in England (65). In Norway a quality 
registry was made for all operated lung cancer patients in a 10-year period from 1993-2002 
(66), but there are otherwise  no nationwide quality registry for lung cancer. No knowledge 
was available on the quality of lung cancer care in a defined hospital region in Norway. 
8.6.2 Minimal important difference (MID) 
MID is defined as the smallest benefit in an outcome that has an impact on the management of 
the disease by clinicians (67). Some use the term ‘minimally clinically important difference’ 
(MCID) (68, 69), and underline the importance of participation of the patients to judge the 
difference in care (70). Such a difference must be meaningful for the patient in addition to 
have an influence on the management of the disease (70, 71). MID can be applied on outcome 
variables in chronic obstructive pulmonary disease (COPD) as six-minutes walk test (72) or as 
quality of life (QOL) (73). In oncology, response to the treatment can give meaningful 
differences for the physicians in endpoints as tumor volume (68), while in a QOL instrument 
as the Functional Assessment of Cancer Therapy – Lung (FACT-L) the patients perception of 
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QOL is taken into account (74). The MID and MCID are important in the calculation of the 
sample size in a study (67, 75). The sample size has to be higher to detect a MID for an 
outcome of low prevalence compared to a high prevalence (76).  At the time of the present 
study (1990 – 96) there were no available studies in Norway based on the whole population of 
lung cancer patients in a hospital defined geographical area. The only source of data was The 
Cancer Registry of Norway (CRN). In spite of a high quality of the data (77) one could 
question how complete the data were, since NCR did not get access to the hospital registries 
before 1998.  
To ensure the quality of the lung cancer management it was a great demand to do a careful 
follow up study on the whole population of lung cancer patients. By applying scientific 
methods a basis was build for comparative studies, both with other parts of Norway and with 
future studies in our own geographical area.  Furthermore, it was a demand to get experience 
in applying scientific methods in the daily clinical work in a non-university institution with 
little tradition in this matter.  
On this background we initiated this retrospective study on all lung cancer patients in the 
hospital area of Haugesund hospital to get answers to the research questions of chapter 9. 
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9. Research questions 
 
The aims of this study including all lung cancer patients in a defined community were to find 
answers to the following research questions: 
9.1 a) What was the incidence of lung cancer by age, gender, UICC anatomical stage of 
tumor and performance status of lung cancer?  b) What predicted the survival in the 
population of lung cancer patients at Haugalandet, Norway?  
 
9.2 How many hospital admissions and hospital days have lung cancer patients from 
diagnosis until death?  
 
9.3 Which symptoms require treatment in the terminal stage of lung cancer? 
 
9.4 a) How is the quality of lung cancer care in our hospital area compared with the rest of 
Norway? b) What are the minimal important differences of lung cancer quality 
indicators for physicians to change their management? 
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10.  Materials and methods 
 
10.1 Study design  
This is a retrospective study of a patient cohort of all incident lung cancer patients at 
Haugalandet in seven years 1990-1996. It is also a longitudinal follow up study of the same 
patient cohort until 31.12.2008. 
10.2 Geographical area 
Haugalandet is located in southwest Norway and included the city of Haugesund and 10 
surrounding municipalities at the time of the study; three from Hordaland County and the rest 
from Rogaland county (figure 6) 
.  
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Figure 6 Map of Haugalandet, Norway, with the 11 municipalities  
                           
 
                                                                                              
Haugalandet with the municipalities Bokn, Etne, Haugesund, Karmøy. Sauda, Suldal 
(northern part), Sveio,Tysvær, Utsira, Vindafjord and Ølen (later Ølen and Vindafjord have 
later merged to one municipality).       
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10.3 Population 
In 1992 the hospital district had 98 316 inhabitants, 49 507 men and 49 809 women (table 1). 
Table 1 Population by gender and age by 11 municipalities at Haugalandet 1. January 1994 
(source: Statistics of Norway) 
Age 0 - 15 16 - 66 67+ Total 
Municipality     
Bokn       M    F 
84 
89 
255 
223 
50 
74 
389 
386 
Etne    M    F 
449 
441 
1247 
1109 
291 
377 
1 987 
1 927 
Haugesund    M    F 
3 013 
2 907 
9 137 
9 026 
1 676 
2 911 
13 826 
14 844 
Karmøy    M    F 
4 434 
4 392 
11 823 
11 162 
1 612 
2 222 
17 869 
17 776 
Sauda    M    F 
574 
552 
1 657 
1 566 
360 
490 
2 591 
2 608 
Suldal    M    F 
502 
468 
1 266 
1 161 
323 
377 
2 091 
2 006 
Sveio    M    F 
644 
572 
1468 
1365 
245 
343 
2 357 
2 280 
Tysvær   M   F 
1 109 
1 029 
2 644 
2 423 
380 
487 
4 133 
3 939 
Vindafjord   M   F 
621 
561 
1 584 
1 351 
346 
434 
2 551 
2 346 
Ølen    M    F 
384 
368 
995 
924 
213 
309 
1592 
1601 
Utsira    M    F 
31 
17 
67 
49 
23 
30 
121 
96 
Total   M   F 
11 845 
11 396 
32 143 
30 359 
5 519 
8 054 
49 507 
49 809 
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10.4 Management of lung cancer patients in Haugesund hospital 1990-96 
Of the patients 63% were referred from primary care physicians and 24% from other 
specialists (table 2). The hospital had only one authorized chest physician who was part of the 
team doing general internal medicine (principal investigator). Younger physicians assisted the 
chest physician. Medical history and clinical examination were obtained on the day of 
admission. Spirometry and chest X-ray were performed on the same or following day, 
followed by computer tomography (CT) scanning and bronchoscopy. In two patients we did 
not obtain the reports from x-ray thorax, but CT was performed. A higher proportion of the 
patients not examined with spirometry (37%) or bronchoscopy (16%, table 2) were older, had 
poorer performance status, more extensive disease and got supportive care only compared to 
those who underwent these procedures (data not shown).   Transcutaneous biopsies of 
peripheral tumors were guided by CT. These procedures were in agreement with international 
textbook recommendations (78). Mediastinoscopy was performed by referral to university 
hospitals. Anatomical staging was done on the basis of X-ray, CT, bronchoscopy, biopsies 
and cytological specimens (79).  
Radiation treatment was given at Haukeland University Hospital, Bergen.  The capacity for 
radiology treatment was low, and the patients had to wait six to eight weeks for palliative 
treatment like other hospitals in Norway (80). Thoracic surgery was for the 5 first years done 
at Haukeland University Hospital or at Stavanger University Hospital depending on the 
patient’s residence. Lung cancer surgery was also performed at Haugesund Hospital in 1994-
96. The role of chemotherapy in NSCLC was not yet established (81) and it was given mainly 
to patients with SCLC.  
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Table 2 Reference pattern, diagnostic procedures and initial treatment in 271 lung cancer 
patients of Haugalandet 1990-96 
N(%) 271(100) 
Referral to hospital from 
  Primary care doctors 
  The National Mass  Radiography Service 
  Other hospitals and health institutions 
  Other specialists (ENT, radiologists, surgeons) 
  Direct contact to lung specialist from the patient 
 
171(63) 
7(3) 
17(6) 
64(24) 
12(4) 
X-ray thorax (report present) 
  Yes 
  No 
 
269(99) 
2(1) 
CT thorax 
  Yes 
  No 
 
227(84) 
44(16) 
Spirometry 
  Yes 
  No 
 
171(63) 
100(37) 
Bronchoscopy 
  Yes 
  No 
 
226(84) 
45(16) 
Initial treatment  
  Surgery (resection) 
  Chemo- and/ or  radiotherapy                      
  Best supportive  care            
 
31(11) 
141(52) 
99(37) 
 
 
 After diagnostic procedures and initial treatment the patients were discharged from the 
hospital, and thereafter ambulant followed as outpatients twice a year. Patients with relapse of 
the disease were only given best supportive care. Regular treatment with opioids was initiated 
in hospital and followed up in a primary health care setting. Second line chemotherapy was 
only given in exceptional cases. Haugalandet had no separate hospice institution, and terminal 
care was provided in the local hospital, in local nursing homes and at home. The 16 nursing 
homes in the municipalities were staffed with nurses and served by a physician at least once 
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weekly.  A palliative care nurse at the hospital made home visits to the patients on a direct 
request by patients or his/hers general practitioner. Patients with advanced disease and 
metastasis were offered direct admission to the local hospital at their own request.                      
10.5 Sources of data  
10.5.1 Haugaland Local Lung Cancer  Registry (LCR). 
All incident lung cancer patients admitted to the hospital in 1990 – 1996 were included in the 
study. Three patients were diagnosed at Haukeland University Hospital, one at Stavanger 
University Hospital and the other 267 at Haugesund hospital. The medical reports from all 
128 patients with 192 admissions in other hospitals (table 3) were collected together with all 
records from Haugesund hospital in one single journal for each patient and stored in a patient 
archive.  
Table 3 Distribution of incident patients with lung cancer 1990-96 admitted in other hospitals 
than Haugesund County Hospital  
 Surgical 
resection 
Radio- and/or 
chemotherapy 
Supportive 
care only 
Total 
Haukeland University 
Hospital 
15 78 4 103b 
Stavanger University 
Hospital and other 
hospitalsa 
11 21 2 28b 
aStord county Hospital, The Norwegian Radium Hospital  
bThree patients were admitted both in Haukeland University Hospital and other hospitals 
 
  
From the archive the patients’ journals were brought to the physicians performing the study. 
The medical records from all patients given from CRN were found in the hospital archives 
and could thus be studied. Patients misdiagnosed or double recorded were excluded (figure 7). 
The diagnosis of lung cancer was defined by neoplastic histology, cytology or convincing 
radiologic signs (chest radiography, CT). 
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10.5.2 The Cancer Registry of Norway (CRN) 
This is population based and receives clinical and pathology reports for all cancer patients in 
Norway. From 1998 information from hospital patient administrative systems and other 
centers dealing with cancer patients are also sources of information. Information from death 
certificates comes in addition.  It is mandatory to report cancer to CRN, and patient’s consent 
is not needed.  Therefore, the completeness of CRN is estimated to be very high (77).  The 
data from the CRN are readily available for the whole country and for each of the 19 counties 
via annual reports and on the website (2), and on the request for health regions and 
municipalities. The stages of solid tumors in CRN consist of three categories which is 
different from the International System of Staging Lung Cancer (appendix 17.1).  About 30 
physicians at Haugesund hospital had participated in filling out the routine forms for CRN, 
according to the law. Information was subtracted regarding gender, age, histology and stage 
for all new patients with lung cancer, as well as on the number of patients that were operated 
on, and their overall survival after 1, 5 and 10 years. Data on other treatment options were not 
sufficiently complete for a further analysis. 
10.6 Inclusion and exclusion of patients 
Inclusion criteria in this hospital area survey were as follows: 1. All new patients in the 
hospital records of Haugesund Hospital with lung cancer in ICD 9 (1990-96). 2. All new 
patients in the CRN with lung cancer in ICD 7, (1990–92) and ICD 9 (1993–96). Hospitalized 
patients diagnosed with lung cancer in the same period but resident outside this hospital area 
were excluded (figure 7). From the hospital records in 1990-96 we found 312 patients (figure 
7) by searching on the diagnosis number according to the International Classification of 
Diseases 9 (ICD-9). However, 21 patients were diagnosed before 1990 (prevalent). Of the 
remaining 291 patients 24 had diagnosis like lymphoma, thymoma, tuberculosis, embolus of 
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the lung, neuroectodermal tumor in mediastinum and liver cirrhosis with ascites. Examples of 
patients reported to CRN with incorrect diagnosis according to the hospital records were 
patients with pleural fluid in heart failure with possible atypical cells, or lung infiltrate with 
atypical squamous cell in bronchial biopsy proven to be tuberculosis. On the other side some 
patients with serious concomitant diseases as the main diagnosis and who also had lung 
cancer were not initially reported to CRN, e.g. a patient with leukemia or patients seriously ill 
from heart disease.  Among the patients with initially incorrect diagnosis from CRN were 
three with metastasis, but without localization of primary tumor, and one with prostate cancer.  
Such patients later got the initial diagnosis changed and were no longer registered as lung 
cancer patients in CRN. 
Twenty-one patients had been diagnosed before 1990 (prevalent cases). Eight patients were 
living outside our hospital area.  From the hospital records 259 patients were thus included in 
the study, and 15 of these were not found in the records from CRN where 264 patients were 
reported.  Three were double recorded and in five patients the diagnosis was not correct. Thus 
256 patients were included from CRN, but 12 of these were not found in the hospital records 
diagnosed with lung cancer and thus 244 patients were common in both records. We were 
however able to trace all these 12 patients in the records of Haugesund Hospital because of 
their birth number, and they had lung cancer. Thus the total number of eligible patients then 
became 271 (figure7, and figure 8). Altogether 214 (78%) were men and 57(22%) were 
women (table 4a, figure 8). 
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Cancer Registry of Norway (CRN)           Haugesund Local Lung Cancer Registry (LCR) 
 
 
 
 
 
3 double 
recorded 
21 prevalent 
261 291 
256 
5 not correct  
diagnosis 
 267 
24 not correct 
diagnosis 
244 244 
15 only in 
LCR 
12 only in 
CRN 
 264 
Total number of patients: 244 +12 + 15  =  271 
259 
312 
8 living outside 
hospital area 
Figure 7 Inclusion and exclusion of patients 
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Figure 8 Incident cases of lung cancer in 214 men and 57 women in Haugalandet area 1990 – 96 
  
 
 
This gives in average 30.6 cases per year in men and 8.1 cases per year in women, in total 
38.7 cases per year.  
10.7 Case record form (CRF) (Appendix 17.6)  
The CRF was developed to collect information about demography, referring procedures, 
number and length of hospital admissions, diagnosis, co morbidity, occupational history, 
smoking status, symptoms and clinical signs. The date for symptoms, diagnosis and deaths 
were noticed.  Furthermore laboratory results, X-ray-findings, diagnostic procedures, 
diagnosis, staging and treatment were recorded. The symptoms and treatment in the terminal 
eight weeks were given special emphasis. A pilot study was performed on 20 patient records 
by an experienced specialist in internal medicine using the case record form, and a semi 
quantification of symptom load was added. Dates of death were collected from the Cancer 
Registry of Norway (1).  Altogether 31 variables of a total of 139 variables regarding 
municipality, referral, comorbidity at diagnosis, occupational history, tobacco history and 
laboratory results were not analyzed for this thesis.  
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Table 4a Variation of patient characteristics of lung cancer among the participating physicians  
extracting data from the patient journals. Demography,stage, performance status, histology, 
treatment, comorbidities and symptoms. 
Variable Participating  physicians Total P (Exact 
Pearson 
chi-square) 
 I II III   
 N(%) N(%) N(%) N(%)  
Total 204(75.3) 44(16.2) 23(8.5) 271(100)  
Gender 
   Male 
   Female 
 
161(79) 
43(21) 
 
33(75) 
11(25) 
 
20(87) 
3(13) 
 
214(79) 
57(21) 
0.54 
Age (years) 
   <65 
   65-74 
   75+ 
 
72(35) 
73(37) 
59(29) 
 
11(25) 
20(46) 
13(30) 
 
9(39) 
8(35) 
6(26) 
 
92(39) 
101(35) 
78(100) 
0.67 
Stage (UICC) 
   1 and 2 
       3 
       4  
 
61(30) 
67(33) 
76(37) 
 
7(16) 
19(43) 
18(41) 
 
5(22) 
10(44) 
8(35) 
 
73(27) 
96(35) 
102(38) 
0.33 
Performance  status (WHO)     
   0 and 1    
        2         
   3 and 4   
 
90(44) 
69(34) 
45(22) 
 
23(52) 
15(34) 
6(14) 
 
12(52) 
4(17) 
7(30) 
 
125(46) 
88(33) 
58(21) 
0.33 
Histology 
   NSCLC 
   SCLC 
   No histology verified 
 
137(67) 
45(22) 
22(11) 
 
28(64) 
12(27) 
4(9) 
 
16(70) 
4(17) 
3(13) 
 
181(67) 
61(23) 
29(11) 
0.91 
Treatment 
   Surgery (resection) 
   Chemo- and/or  radiotherapy 
   Best supportive therapy only  
 
25(12) 
103(51) 
76(37) 
 
5(11) 
23(52) 
16(36) 
 
1(4) 
15(65) 
7(30) 
 
31(11) 
141(52) 
99(37) 
0.69 
Heart disease 
   Yes 
   No 
 
50(25) 
154(76) 
 
13(30) 
31(71) 
 
7(30) 
16(70) 
 
70(26) 
201(74) 
0.72 
 
Obstructive lung disease 
   Yes 
   No 
 
47(23) 
157(77) 
 
16(36) 
28(64) 
 
2(9) 
21(91) 
 
65(24) 
206(75) 
0.04 
Cough 
   Yes 
   No    
 
80(39) 
124(61) 
 
24(55) 
20(46) 
 
8(35) 
15(65) 
 
112(41) 
159(59) 
0.15 
Dyspnea 
   Yes 
   No 
 
80(39) 
124(61) 
 
29(66) 
15(34) 
 
8(35) 
15(65) 
 
117(43) 
154(57) 
0.003 
Chest pain 
   Yes 
   No 
 
56(28) 
148(73) 
 
15(34) 
29(66) 
 
8(35) 
15(65) 
 
79(29) 
192(71) 
0.59 
Weight loss 
   Yes 
   No 
 
56(28) 
148(73) 
 
16(36) 
28(64) 
 
7(30) 
16(70) 
 
79(29) 
192(71) 
0.49 
Reduced general condition 
  Yes 
   No 
 
104(51) 
100(49) 
 
29(66) 
15(34) 
 
11(48) 
12(52) 
 
144(53) 
127(47) 
0.17 
Skeletal pain 
   Yes 
   No 
 
21(10) 
183(90) 
 
2(5) 
42(96) 
 
5(22) 
18(78) 
 
28(10) 
243(90) 
0.08 
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We counted all the symptoms at the time of the diagnosis mentioned in the CRF, and when 
nothing was mentioned e.g. on chest pain, this was counted as ‘no chest pain’.  The three 
physicians who extracted data from the hospital records into the CRF carried out meetings to 
discuss this process. The principal investigator examined 204 cases, the second 44 cases and 
the third 23 cases (tables 4a and 4b). No overt differences were observed among the three 
recording physicians for the patient characteristics of demography, staging, histology, 
treatment, comorbidity and initial symptoms. However, the prevalence of treatment symptoms 
like pain, cough, anxiety and depression varied between the physicians (table 4 b).  
The grouping of lung cancer in four stages was done according to International Union of 
Cancer Control (UICC) based on the extent of the primary tumor and lymph nodes and the 
presence of distant metastasis (appendix 17.1) (82).  Performance status was graded into five 
groups (appendix 17.2); from zero with the ability to carry out all normal activities without 
restriction to four where the patient is completely disabled (83).  To get complete data about 
the staging and the performance status was a challenge since it was done several years after 
the initial examination of the patients (this problem is also discussed in the method chapter 
12.1.4).  
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Table 4b Distribution of characteristics of lung cancer patients among the three examining 
physicians according to place of death in 253 patients and terminal symptoms in 247 patients 
with lung cancer 
Variable Participating  physicians Total P 
(Exact 
Pearson 
chi-square) 
 I II III   
 N(%) N(%) N(%) N(%)  
Place of death (total) 
   At home 
   In Haugesund hospital 
   In nursing home 
   Other hospitals 
   Unknown 
187(100) 
19(10) 
106(57) 
57(31) 
4(2) 
1(1) 
43(100) 
6(14) 
23(54) 
13(30) 
0(0) 
1(2) 
23(100) 
4(17) 
13(57) 
3(13) 
3(13) 
0(0) 
253(100) 
29(12) 
142(56) 
73(29) 
7(3) 
2(1) 
0.06 
Terminal symptoms 185(100) 39(100) 23(100) 247 (100)  
Terminal pain 
   No pain 
   Pain, but not treated 
   Peripheral analgetics 
   Opiates 
   Opiates via pain infuser 
 
21(11) 
2(1) 
38(21) 
109(59) 
15(8) 
 
11(28) 
0(0) 
2(5) 
17(44) 
9(23) 
 
4(17) 
0(0) 
4(17) 
12(52) 
3(13) 
 
36(15) 
2(1) 
44(18) 
138(56) 
27(11) 
0.01 
Terminal dyspnea  
   Central obstruction 
   Pleural fluid 
   Other reasons 
   No dyspnea 
 
34(18) 
30(16) 
30(16) 
91(49) 
 
7(18) 
7(18) 
11(28) 
14(36) 
 
7(30) 
2(9) 
6(26) 
8(38) 
 
48(19) 
39(16) 
47(19) 
113(46) 
0.28 
Terminal cough 
   Present, but not treated 
   Treated 
   No cough 
 
35(19) 
11(6) 
139(75) 
 
6(15) 
8(21) 
25(64) 
 
3(13) 
5(22) 
15(65) 
 
44(18) 
24(10) 
179(73) 
0.02 
Terminal nausea 
   Present, but not treated 
   Treated 
   Not present 
 
6(3) 
47(25) 
132(71) 
 
1(3) 
7(18) 
31(80) 
 
2(9) 
3(13) 
18(78) 
 
9(4) 
57(23) 
181(73) 
0.38 
Terminal hemoptysis 
   Present, but not treated 
   Treated 
   Not present 
 
9(5) 
5(3) 
171(92) 
 
5(13) 
0(0) 
34(87) 
 
2(9) 
0(0) 
21(91) 
 
16(7) 
5(2) 
226(92) 
0.24 
Terminal anxiety/depression 
   Present, but not treated 
   Treated 
   Not present 
 
0(0) 
139(75) 
46(25) 
 
4(10) 
16(41) 
19(49) 
 
1(4) 
16(70) 
6(26) 
 
5(2) 
171(69) 
71(29) 
<0.01 
Terminal neurological signs 
   Present, but not treated 
   Treated 
   Not present 
 
12(7) 
47(25) 
126(68) 
 
1(3) 
4(10) 
34(87) 
 
0(0) 
4(17) 
19(83) 
 
13(5) 
55(22) 
179(73) 
0.10 
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10.8 Tobacco smoking and occupational exposure 
The incompleteness of the routine hospital records on tobacco smoking and occupational 
exposure is given in table 5, and with this high proportion of insufficient history no further 
analyses were done on this data. 
Table 5 Hospital information on smoking and occupational history of 271 lung cancer patients 
in the case histories of Haugesund county hospital 1990 – 96  
 
Tobacco history 
  Absent 
  Poor  
  Good (information about amount or duration) 
  Very good (information in pack years) 
N(%) 
 
16(6) 
    80(30) 
107(30) 
68(25) 
 
Occupational history 
  Not present 
  Poor (only one occupation, no duration) 
  Good  (both more occupations and duration) 
  Very good (detailed from start of work to the last 
  occupation) 
 
 
55(20) 
129(48) 
61(23) 
 
26(10) 
 
10.9 Survival   
The survival time was counted as the number of days between the date of confirmed diagnosis 
and the date of death.  Date of diagnosis was the date of confirmed histological or cytological 
confirmation, or if morphological data were not available, the date of radiological diagnosis.  
For those patients who died outside the hospital, the date of death was obtained from the 
central population registry and the CRN. The specific causes of death were obtained from 
Statistics Norway. The delay time was defined as the time between onset of the first symptom 
caused by the lung cancer and diagnosis as stated above.    
10.10 Hospital admissions and days  
The stays were categorized in three groups: 1. Diagnostic hospitalization, i.e. days in hospital 
necessary for acquiring a definite diagnosis; 2. Terminal hospitalization, i.e. hospital days 
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within the last 8 weeks of life; and 3. Other hospital days. Admission and departure days were 
counted as whole hospital days. The days in nursing homes were counted separately.  
10.11 Terminal symptoms   
Terminal symptoms during the last eight weeks of life were extracted from the patients’ 
records (page five in the case record form, appendix 17.6). Pain was graded according to its 
intensity defined by the use of peripheral analgesics, opioids or a morphine infuser. The 
presence and possible causes of dyspnea were recorded (central stenosis when a tumor was 
observed on bronchoscopy, pleural fluid observed on chest x-rays or other reasons). 
Psychological symptoms were recorded in patients’ files and defined according to the 
prescribed drugs  in the ATC-classification system (84): depression, when given 
antidepressive medication (N 06), anxiousness, when given diazepam (N05 B A 01) or other 
anxiolytic treatments (N05 B A 04), or insomnia when given hypnotics (N 05 C). Dizziness, 
headache or signs of paresis were defined as neurological symptoms but the records did not 
require treatment intervention. Additional terminal symptoms recorded were nausea, cough 
and hemoptysis.  The number of weeks in the terminal 8 weeks treated for pain, psychological 
symptoms and dyspnea was recorded.  The principal investigator visited the nursing homes 
and interviewed the primary care doctors to get this information of the patients who died 
outside hospital.  
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10.12 Quality of lung cancer care 
10.12.1Quality indicators 
We compared four quality indicators: Staging, histology, resectional surgery and one year 
survival.  Lung cancer care should be performed according to evidence based guidelines (85), 
and quality indicators are then developed to measure the adherence to guidelines and to make 
comparisons of the quality of lung cancer care between management units possible (60, 86).  
Thus we had to find quality indicators possible to measure both in CRN and LCR.  About 30 
physicians at the Haugesund county hospital participated in filling out the routine forms for 
CRN, according to the law. Information was subtracted regarding gender, age, histology and 
stage for all new patients with lung cancer, ICD 7 (1990–92) and ICD 9 (1993–96), as well as 
on the number of patients that were operated on, and their overall survival after 1, 5 and 10 
years. Data on other treatment options were very incomplete for further analysis 
10.12.2   Minimal important differences (MID) in quality indicators 
Twenty-six physicians at the Department of Thoracic Medicine, Haukeland University 
Hospital, Bergen, filled out a questionnaire on what they felt was a meaningful and relevant 
percentage difference from the national average regarding quality indicators that should lead 
to the implementation of changes in their own management of lung cancer (appendix 17.3). 
These indicators included the proportion of patients with no histological confirmation, 
unknown staging, surgical treatment, and one-year survival. The mean age of the physicians 
was 41.3 (SD 10.6) years. Seven physicians were women and 14 had four years or more of 
training in a chest clinic. They were informed on the national average of the four quality 
indicators for the period from 1990 to 1996. Each physician was asked to tick a box of pre-
recorded relative differences (5, 10, 20, 30, 40, 50, 75 or 100%) that would change their own 
management program. 
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10.13 Data handling 
The records from hospitals, nursing homes and general practitioners were reviewed randomly 
by three physicians following instructions given by the principal author.   During this process 
they had meetings where the interpretation and coding were discussed.   The CRF forms were 
then scanned optically into an Excel work sheet, before analysis.   The overall agreement 
among the three physicians in the recorded characteristics of the lung cancer patients is given 
in table 4a and 4b.  
10.14 Statistical analyses 
The case record forms were scanned into a Microsoft Excel worksheet and then imported into 
a statistical software package (SPSS for Windows; SPSS, Inc; Chicago IL, versions 11.5 - 
17.0) for analyses. 
Pearson’s Chi-Square test was used to analyze the differences in categorical variables 
between groups of patients defined by gender, age groups, anatomical stage, performance 
status, histology, treatment and symptoms.  
Kaplan-Meier (87) curves and log rank tests (88)  were used in analyzing differences in 
continuous variables with censored observations as days in hospital and survival time between 
the groups of patients. 
The unadjusted hazard ratio (HR) and 95% confidence interval (CI) were estimated for each 
factor in a Cox proportional hazards regression model (89) both for hospital days (paper II) 
and survival time (paper III). Adjusted HR and 95% CI were estimated from a multiple Cox 
regression model using backward stepwise selection of variables. 
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The Mantel-Haenszel test (90) was used to compare the one-year survival in the two patient 
cohorts between Haugalandet and the rest of Norway, stratified for gender, age, stage and 
histology  (paper IV). 
A logistic regression analysis (91) of one-year survival adjusted for gender, age, histology, 
stage and living place was done in paper IV and reported as odds ratios (OR) and 95% CIs.  
To calculate the sample size (paper IV) to obtain a deviation of 20% on 5% significance level 
with a power of 80% from the national average the SPSS program Sample Power 2.0 was 
used. 
A significance level of 0.05 was applied for all statistical tests.  
10.15 Ethics  
Our study was approved by the Regional Committee for Medical Research Ethics of Western 
Norway. 
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 11 Synopsis of the papers/main results  
Paper I  
The aims of this paper were to study the survival and the predictors of survival in all lung 
cancer patients in a defined population and to determine whether and how the length of time 
from symptom onset to confirmed diagnosis (delay time) influenced survival. All incident 
cases from the Norwegian Cancer Registry and the hospital records in the Haugalandet area 
from 1990–1996 were followed until 31 December 2008. The dates of symptom onset, 
diagnosis, death and information about demographics, initial stage, performance status, 
histology, and initial symptoms were recorded.  
There were 271 incident lung cancer patients from 1990 to 1997. The mean age (SD) at the 
diagnosis was 67.4 (11.2) years, and 57 (21%) were women.    The diagnosis was confirmed 
by histology in 242 patients (89%). The distribution of age, stage, performance status and 
histology at the time of initial diagnosis (table 6a) did not differ between genders (p > 0.05).   
Eighteen (6.6%) were alive by January 1st 2000. One-year survival was 29.2%, and five- and 
10-year survival was 8.5% and 5.5%, respectively. The median (inter quartile range, IQR) 
survival time was 5.7 (1.9,14.1) months and the median (IQR) delay time was 2.2 (1.1,3.7) 
months. Twenty-five patients (10% of those who died) had a non-lung cancer cause of death. 
No weight loss, at the time of diagnosis, was a significant predictor for long survival in 
addition to younger age, limited stage, good functional performance and surgical treatment, 
but delay time for diagnosis had no effect on survival time for lung cancer. 
We conclude that in the whole population of lung cancer patients, long-term survival remains 
poor and is not influenced by diagnostic delay time.  
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Paper II 
All incident lung cancer patients in the Haugalandet area in South West Norway from 1990 
through 1996 were followed from diagnosis till either death or end of follow-up 1 Dec 2003. 
Initial symptoms, anatomical stage, functional performance status, histology, initial treatment, 
terminal care, number of admissions as well as days of hospitalization were recorded.  Of a 
total of 271 patients (57 women) only 16 were still alive at end of follow up. Median survival 
time was 170 days. Mean age at the first admission was 67.4 years (range 21 - 89 years). 
Median number (inter quartile range, IQR) of admissions was 3 (2, 5) and total hospitalization 
days were 35 (18, 58). Altogether 26% of the days in institutional care were spent in nursing 
homes. Thirty one patients surgically treated had 75 (56, 96) days of hospitalization, which is 
the highest number of admission days. Young age, low anatomical stage and good 
performance status at time of diagnosis were associated with increased hospitalization days. 
The effects of age, tumor stage and performance status were non-significant in a Cox 
regression analysis when adjusting for treatment interventions.   
We conclude that in a population-based cohort of incident lung cancer patients, days in health 
care institutions involved a considerable part (19%) of all survival time for those who died. 
However the absolute number was greater for those with small tumors and high functional 
performance status which initiated other interventions than only palliative treatment.  
Paper III      
We examined, retrospectively, all the cases of lung cancer diagnosed from 1990 to 1996 in a 
defined hospital area in Norway with regard to the symptoms in the terminal 8 weeks of life.  
All medical records from general practitioners, nursing homes, and hospitals were 
investigated. A total of 271 cases were diagnosed, and 247 of 253 deaths (98%) were 
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analyzed. One patient died abroad, and the records of 5 patients were not available.  Only 53 
(22%) of the 247 deaths were women.   
Pain was recorded in 85% of the patients, psychological symptoms (anxiety, insomnia, and/or 
depression) in 71%, dyspnea in 54%, neurologic symptoms in 28%, cough in 24%, nausea in 
21%, and hemoptysis in 9%. Young age (p < 0.02) and small cell lung carcinoma (SCLC)  
(p< 0.03) were risk factors for psychological symptoms. Terminal dyspnea was more frequent 
in patients with stage III (p < 0.002) and nausea in stage IV (p < 0.02) at the time of 
diagnosis, while cough (p < 0.04) occurred more often in non-small cell lung carcinoma 
(NSCLC). 
Terminal pain was independent of gender, age, performance status, stage, and histology. 
We concluded that in a community health service encompassing all lung cancer patients, pain, 
psychological symptoms, and dyspnea were frequent complaints in the terminal phase. 
Terminal dyspnea and nausea were associated with staging at the time of diagnosis, terminal 
cough with NSCLC and nausea with SCLC.  
Paper IV   
We compared four quality indicators (staging, histology, resectional surgery and one year 
survival) in 271 patients recorded in a local lung cancer registry (LCR) with 266 patients 
recorded in the Cancer Registry of Norway (CRN) from Haugalandet hospital area and         
12 428 patients from the rest of Norway for an identical period of time.  The average minimal 
difference of clinical importance, as judged by the physicians, for the four lung cancer quality 
indicators varied between 18% and 23%. Percentages regarding histology, resectional surgery 
and one year survival did not differ between LCR and CRN. However, fewer patients had 
localized disease in the LCR than in the CRN. The differences in relative percentage between 
Haugalandet and the rest of Norway were 3% for unknown stage, -6% for unknown histology, 
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-20% for surgery and -5% for one year survival. The sample sizes necessary to detect a 
relative 20 % difference from the national average (power 0.80, p<0.05) were from 435 cases 
to 2826 cases depending on which indicator was chosen.  
Quality indicators from two lung cancer registries were in agreement in a population recorded 
for the same time and area, and did not differ from the rest of the country with the exception 
of stage. Small regional management units should merge to a larger unit with standardized 
procedures which include at least 250 incident lung cancer patients per year. We could thus 
estimate quality indicators of lung cancer care for comparisons with national averages, and 
with other management units. A national lung cancer quality registry should be established. In 
addition to quality indicators of today discussed in this study one should include: 1. Modern 
TNM-classification (UICC),   2. Performance status, and 3. More accurate information on 
interventions, follow up and final outcome.  Such a registry could then be a tool to improve 
the quality of lung cancer care in Norway.  
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12   Discussion 
12.1 Methodological considerations 
12.1.1 Study design.   
The study is retrospective, which implies some limitations. In a retrospective study one can 
observe connection between variables, and thus it can generate hypothesis, but not give 
information about causal relationship.  
12.1.2 Patient selection 
The patients were found by searching in the hospital records on the ICD-diagnosis number, 
either as main diagnosis or additional diagnosis. Also the search from CRN was based on 
diagnosis number. At the time of the study, CRN had no access to the hospital registries, and 
was based on cancer reports from institutions and doctors in addition to death certificates.  A 
lung cancer patient missing in LCR and not reported, e.g. due to misdiagnosis, could therefore 
also be missed in CRN (see chapter 10.6).   
Originally we had an intention to estimate the completeness of the data in both CRN and the 
LCR.  Since these two institutions had some communication during the planning of the study 
and extraction of data, this may have improved the quality and the completeness in the patient 
cohorts which we examined, by removing some mistakes. At the first contact between the 
hospital and CRN there were errors in both registries (figure 7) with incorrect diagnosis or 
lack of records in the registries. No records were available for 15 (5.5%) lung cancer patients 
in CRN and for 12 (4.4%) of the lung cancer patients in LCR.   
Two measures have the potential to improve the quality of CRN and thus obtain high quality 
data in future studies. Firstly, in the new electronic journal systems in the hospital the report 
form may now be filled out electronically at the same time as the doctor makes the report to 
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the referring doctor. This improves the quality of the reports compared to the earlier ones 
when the paper forms were filled out separately often a long time after the initial 
examinations. Secondly, from 1998 CRN got access directly to the hospital registries, thus 
improving the completeness in the reporting.  
12.1.3 Case record form 
Hospital admissions and days were recorded on the CRF (appendix 17.5), but outpatient visits 
were not recorded. From 1995 – 1996, some of the bronchoscopy procedures were done 
ambulant. Future studies should record outpatient visits and procedures applied at outpatient 
visits as well as procedures at hospital admissions. 
12.1.4  Validity 
12.1.4.1 Internal validity 
Internal validity may be threatened by 1. Selection bias, and 2. Information bias   
1. Selection bias. We attempted to get the cohort of lung cancer patients as complete as 
possible by a careful search in our own hospital registry and by repeatedly contacting with 
CRN (figure 7). Since we were able to retrieve all patients from CRN, also those who had not 
got the lung cancer diagnosis from the beginning in our hospital registry, we consider the 
selection bias to be small.  Two patients living in the Haugesund hospital area were initially 
diagnosed at Haukeland University hospital and  one patient diagnosed at Stavanger 
University Hospital the CRF-forms filled out on account of the records in these hospitals 
(table 3). 
2. Information bias.  Retrospective data based on the routine work in a busy local 
hospital may be incomplete for scientific purpose due to both missing information and 
missing notes (92). Both occupational and smoking history were significantly incomplete 
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(table 5). To extract the information from the original hospital notes from the patients (notes 
from doctors and nurses, referring letters, x-ray pictures and descriptions, results from 
laboratory and other examinations) into a structured case record form could also imply 
inaccuracy. To get complete information on performance status we searched not only in the 
doctors’ records, but also in the hand written records from the nurses, who carefully had 
recorded the general condition of the patients, e.g. if they were linked to bed, or if they could 
walk and be able to care for themselves in activities of the daily life. To minimize bias the 
three physicians had meetings both before and during this process to discuss how to transfer 
the findings in the patient records into the CRF-forms.  
12.1.4.2 External validity 
Are these results applicable to a population outside Haugalandet, as to the Norwegian 
population?  
There was a slightly higher proportion of younger people at Haugalandet than in the whole 
Norway but no difference in the gender (table 6).  
Table 6 Distribution of men and women and age groups in the population at Haugalandet 
compared to the whole population of Norway in 1994 (source: Statistics Norway) 
 Haugalandet 
N(%) 
Norway 
N(%) 
Gender   
   Males 49 507(49.8) 2 138 628(49.5) 
   Females 49 809(50.2) 2 186 187(50.5) 
   
Age (years)   
   0-15 23 241(23.4) 888 561(20.5) 
  16-66 62 502(62.9) 2 815 503(65.1) 
   67+ 13 573(13.7) 620 751(14.4) 
Total 99 316(100.0) 4 324 815(100.0) 
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We compared our lung cancer patient cohort with all patients in the rest of Norway, based on 
information from CRN (paper 4). There were less female lung cancer patients at Haugalandet 
compared to the rest of Norway, but histology, stage, surgical treatment and one year survival 
did not differ.  As seen in figure 3 there are variations in the incidence of lung cancer between 
the counties in Norway. It is difficult to find evidence based knowledge for these differences. 
Some possibilities are suggested. There may be different cigarette consumption in various 
counties. In the Agder counties 88% of ever-smokers had smoked primarily hand-rolled 
cigarettes  (93). Melting industry and ship-yard industry with potential occupational 
exposures are more frequent at the coastal area in West-Norway than in the inland. There are 
differences in radon exposures between geographical areas in Norway, as discussed in the 
introduction (chapter 8.2.2).  We hypothesize that cigarette smoke and occupations with lung 
cancer risks were less prevalent for women at Haugalandet compared with the rest of the 
country before the 1990-ties.  
However, since distribution in the population in Haugalandet and the whole Norway is similar 
regarding age of men, we may assume that the results from the local patient cohort are 
comparable to the results from other population-based lung cancer patient cohorts in Norway 
regarding men. 
When comparing the number of hospital days, the management units in other regions with 
more dense population than Haugalandet may have more of the lung cancer care on an 
outpatient basis. 
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12.2 Discussion of main results 
12.2.1 Incidence of lung cancer 
In this population based study we found 271 incident cases of lung cancer in 11 municipalities 
at Haugalandet from 1990-96 of whom 57 (21%) were women (table 4a). This means in 
average 38.7 new cases per year; 8.1 women and 30.6 men in a total population of 99 316 
inhabitants in 1993 (figure 8).  
From CRN the total number of new cases in the same period of time was 260 (table 7). There 
may be various reasons why the CRN has a lower total incidence of lung cancer patients than 
LCR. Before 1998, this registry had no direct access to the hospital registries. Furthermore 
CRN is never closed, which means that when new information about patients becomes 
available even years after first registration the register may be adjusted.   
There was a lower incidence of women with lung cancer at Haugalandet compared with the 
rest of the country both in LCR and CRN (paper 4).  The proportion of women was also 
higher (27%) in a hospital-based cohort diagnosed at Nordland Central Hospital 1987-92 (23) 
compared to Haugalandet. In a prospective study from Aust- and Vest-Agder  counties, 42% 
of the patients diagnosed from 2002 - 2005 were women (94). In addition to a possible higher 
proportion of women in Agder compared to 21% at Haugalandet, this difference may also 
reflect the increasing number of women with lung cancer since the inclusion was 10 years 
after our study. Several studies from Norway have shown the association between cigarette 
smoking and lung cancer (20, 95). Recent national data show that the proportion of women 
has increased and the proportion of men with lung cancer has decreased the last years (figure 
5), and this is also our clinical experience from Haugalandet the last decade.   
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Comparisons of incidence rates have to use age-adjusted incidence rate according to WHO 
World Standard Population  (96).  When comparing Haugalandet with the counties Rogaland 
and Hordaland, it was a trend towards a lower incidence rate in women at Haugalandet, and 
this was more pronounced when compared with all patients in Norway (table 7). 
Table 7 Number of new cases and age adjusted incidence rates per 100 000 per year in 
Haugalandet and Norway for 1990-96, and Rogaland and Hordaland counties for 1991-1995 
(source: Cancer Registry of Norway) 
    Males Females 
Haugalandet 
1990-1996 
Number 202 58 
Age-adjusted incidence rate 39.9 10.8 
Norway  
1990-1996 
Number 8 557 3874 
Age-adjusted incidence rate 36.3 15.3 
Rogaland 
1991-1995 
Number 427 168 
Age-adjusted incidence rate 37.3 13.2 
Hordaland 
1991-1995 
Number 572 211 
Age-adjusted incidence rate 36.7 12.3 
 
The trend of a lower proportion of women at Haugalandet  compared with the whole country 
was also seen when comparison was made for each year. In men the age-adjusted incidence 
rate was similar for the two cohorts (tables 7 and 8).  
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Table 8 New cases  per year and age-adjusted incidence per 100 000 per year at Haugalandet 
compared with Norway 1990-1996  in 260 patients with lung cancer reported in the Cancer 
Registry of Norway.  
    Haugalandet Norway 
    Number Age-adjusted rate Number Age-adjusted rate 
1990 
Males 30 43.3 1175 35.0 
Females 6 9.7 478 13.3 
Total 36 25.3 1653 23.1 
1991 
Males 32 47.2 1160 35.1 
Females 4 6.8 511 14.0 
Total 36 25.9 1671 23.6 
1992 
Males 23 31.3 1203 35.8 
Females 6 7.6 502 13.9 
Total 29 18.5 1705 23.8 
1993 
Males 29 39.9 1244 37.3 
Females 5 5.8 545 15.5 
Total 34 21.7 1789 25.3 
1994 
Males 24 32.9 1244 36.7 
Females 14 17.8 565 15.7 
Total 38 24.6 1809 25.1 
1995 
Males 34 47.8 1241 36.2 
Females 11 13.1 598 15.8 
Total 45 29.4 1839 25.0 
1996 
Males 30 39.1 1290 37.7 
Females 12 14.5 675 18.6 
Total 42 25.7 1965 27.2 
 
The average  age at the diagnosis of 67.4 years in Haugalandet correspond with the rest of 
Norway (paper 4), and also with the population based study from Aust- and Vest-Agder 
counties 10 years later with a mean age of 67.9 years (94).  In the hospital based cohort in 
secondary care in Nordland county the mean age was 65.5 years (23), and in tertiary care at 
Rikshospitalet, Oslo, the mean age of patients discharged with lung cancer 1962 – 71 was 65 
years for men and 60 years for women (97). However, the oldest and most sick patients were 
probably not referred to this tertiary care hospital for further diagnosis and treatment in these 
time periods.  
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The distribution of stages in our patient cohort was 38% for stage IV (82) similar to the rest of 
Norway as found in CRN (paper 4). Lower stages are impossible to compare since CRN has a 
different staging. In our cohort from Haugalandet 38 % were in stage Ia – IIIa, and 62% in 
IIIb – IV (table 9), slightly different  to the population based study from Agder counties with 
corresponding proportions of 28% and 72%  (59) and similar to the selected cohort from 
Nordland county with 63% of the patients in stage IIIb and IV (23).  
The proportion of SCLC of 23% (Table 9) in Haugalandet corresponds with 19% in the rest of 
Norway and with 24% and 21% in the two other recent Norwegian studies (23, 93). Initial 
surgical treatment was given to 11% of our patients (table 9) which is a lower percentage than 
in the recent population-based study from Agder county with 16% (98), and in the rest of 
Norway (paper 4) with 16%.  One reason for this could be different attitudes to and 
indications for lung cancer surgery at Haukeland University Hospital in 1990-96 compared to 
other units of thoracic surgery in Norway.   
 
 
 
54 
 
Table 9 Age, gender, anatomical stage, performance status, histology, initial treatment, and 
referral sources in 271 lung cancer patients 1990-96, Haugesund County Hospital. 
Total n (%)  271(100) 
Age (years) mean(SD)          67.4(11.2) 
Men    
Women   
214(79.0) 
57(21.0) 
Anatomical stage (UICC 1997) 
Ia n(%)  
Ib n(%)  
IIa n(%)  
IIb n(%)  
IIIa n(%)  
IIIb n(%)  
IV n(%)  
 
 
13(4.8) 
37(13.7) 
2(0.7) 
21(7.7) 
29(10.7) 
67(24.7) 
102(37.6) 
Performance  status     
   0 and 1    
   2         
   3 and 4   
 
125(46.1) 
88(32.5) 
58(21.4) 
Histology 
  Small cell carcinoma               
  Adenocarcinoma  
  Squamous cell carcinoma             
  Non-differentiated carcinoma             
  Other lung cancer.   
  No tissue  diagnosis 
 
61(22.5) 
75(27.7) 
59(21.8) 
34(12.5) 
13(4.8) 
29(10.7) 
Initial treatment  
  Surgery resection) 
  Chemo- and/ or radiotherapy                      
  Best supportive care            
 
31(11.4) 
       141(52.0) 
99(36.5) 
Referral to hospital from 
  Primary care doctors 
  The National Mass  Radiography Service 
  Other hospitals and health institutions 
  Other specialists (ENT, radiologists, surgeons) 
  Direct contact to lung specialist from the patient 
 
171(63.1) 
7(2.6) 
17(6.3) 
64(23.6) 
12(4.4) 
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12.2.2 Survival in lung cancer 
In this study of an unselected cohort of lung cancer patients from a defined geographical area 
we found a median survival of 5.7 months, and a one year and five year survival of 29.2% and 
8.5%, respectively. Younger age, limited disease, surgical treatment, good performance status 
and no initial weight loss were predictors of long survival. We did not find that the time 
between symptom onset and diagnosis predicted survival.  In an early Norwegian study from 
tertiary care in 1053 patients with lung cancer diagnosed from 1962  to 1971, the five year 
survival was  15.5% (99). The duration of symptoms when present did not influence the 
survival, and extensive disease and old age were unfavorable prognostic factors as in our 
study from Haugalandet.  
The overall five-year survival in lung cancer has not changed markedly in Norway the last 40 
years (figure 1), but a trend in the last years of a moderate increase in survival in women is 
observed (5).  In a recent study from Norway female gender was a predictor for long time 
survival in a selected population of lung cancer patients offered surgery (100). We have found 
17 clinical lung cancer studies from Norway published in the last 10 years (table 10a+10b), 
and we want to discuss their observations in the context of lung cancer patients at 
Haugalandet.   
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Table 10a Clinical studies of lung cancer patients in Norway published 2001- 2007 
Author/ 
year of 
 publication 
(reference) 
Years 
of 
patient 
diag-
nosis 
Number  
of 
 patients 
Mean 
age 
(years) 
Gender 
% 
women 
Stage Histo-
logy 
Median 
suvival 
(months) 
One 
year 
sur-
vival 
% 
Five  
year 
sur-
vival 
% 
Alexandersen 
 
2001 (23) 
 
1987-
92 
 
 
219 
 
 
 
65.5 
 
25  
 163 
NSCLC 
28% 
stageI+II 
72% 
stageIII+
IV 
76% 
NSCLC 
24% 
SCLC 
 
 
NA 
 
NA 
 
10 
Bremnes 
2001 (101) 
Chemo-
therapy 
1996-
98 
 
39 
 
Median: 
63 
46  L.D. SCLC 
 
21 69 NA 
Dahle 
2003 (102) 
Surgery 
1993-
98 
99 63 31 I-IIIa 89 
IIIB-IV 9 
NSCLC 30 NA NA 
Bremnes 
2003 (103) 
Chemo-
therapy 
1989-
94 
436 
 
Median: 
64 
36 
 
51% 
E.D. 
SCLC 
 
9 
(LD – 13  
ED -  7 ) 
NA NA 
Sundstrøm 
2004 (104) 
Palliative 
radiotherapy 
1993-
98 
421 Median: 
68 
23 
 
St. III : 
77% 
IV: 23% 
NSCLC 
 
NA 29 NA 
Batevik 
2005 (105) 
Surgery 
1988-
2002 
351 
 
64 32 
 
I : 71% 
II: 15% 
III: 15% 
NSCLC 
 
NA NA 46 
von Plessen 
2006 (106) 
(Chemo-
therapy) 
2000-
02 
297 
 
65 37 
 
IIIb: 24% 
 
IV: 76% 
 
NSCLC 
 
7.7 C3:25 
C6:25 
NA 
Sundstrøm 
2006 (107) 
Pall. radioth. 
(A,B and C) 
1993-
98 
301 Median: 
68 
23 St. IIIa: 
18% 
IIIB: 
82% 
NSCLC 
 
A: 9.2 
B:7.5 
C:7.5 
 
 
     0 
6 
3 
Hellbekkmo 
2007 (108) 
Chemo-
therapy 
2003-
04 
432 
 
 
Median: 
67 
39  IIIb: 39% 
 
IV: 61% 
NSCLC 
 
 
NA 
 
29 
 
NA 
 
SCLC  = Small cell lung cancer, NSCLC = Non-small cell lung cancer, L.D. = Local disease, E.D. = Extensive 
disease, m = months, NA = Not available 
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Table 10b Clinical studies of lung cancer patients in Norway published since 2008 
Author/year 
of 
 publication 
Years 
of 
patient 
diag-
nosis 
Number  
of 
 patients 
Mean 
age 
(years) 
Gender 
% 
women 
Stage Histo-
logy 
Medi-
an sur-
vival 
months 
1 y 
Sur-
vival 
% 
5y 
Sur-
vival 
% 
Hermes, A 
2008 (109) 
Irin+carbo 
Etopo+carbo 
2001-
05 
209 Median 
 
67 
68 
34 
 
E.D. SCLC 
 
  8.5m 
7.1m 
NA NA 
von Plessen 
2008 (110) 
Chemo-
therapy 
1994-
2005 
13 757 
 
67.5 35 Regional
ly 
advanced  
27% 
Met 23% 
NSCLC 
 
94-97: 
5 
2000-
05: 
6 
NA 2.5 
Roth 
2008 (111) 
Surgery 
1993-
2006 
 
148 
 
 
67.3 
 
32  
IA:43% 
IB:46% 
II-IV: 
11% 
NSCLC 
 
71 82 42 
Al-Shibli  
2009 (112) 
Surgery 
1990-
2004 
 
335 
 
Median 
67 
25 
 
I : 27% 
II : 65% 
IIIa: 8% 
NSCLC 
 
109 
 
NA 57 
Grønberg 
2009 (113) 
Chemo-
therapy 
2005 36 
 
Median 
61 
29 
 
LD SCLC 
 
4 1/2 NA NA 
Grønberg 
2009 (114) 
Chemo-
therapy 
 
2005-
06   
436 Median 
 
65 
42 St IIIB : 
40% 
Stad IV: 
60% 
NSCLC 
 
7.1 32 NA 
Strand 
2010 (115) 
Radiation 
 
1993-
2001 
497 65 32 
 
I+II: 
29% 
IIIa+IIIb: 
70% 
NSCLC 
 
NA 53 9 
Hjelde   
2010 (116) 
Surgery  
 
1994-
2001 
190 66 39 I+II:81% 
III+IV: 
19% 
NSCLC 
 
 
NA NA 42 
Skaug 
2011 (117) 
Population 
based 
1990-
96 
271 67.4 
Median: 
69  
21  
 
I+II : 
27% 
III+IV 
73% 
Un-
selected 
 
5.7 29 8.5 
 
SCLC  = Small cell lung cancer, NSCLC = Non-small cell lung cancer, L.D. = Local disease, E.D. = Extensive 
disease, m = months, NA = Not available 
 
These studies are heterogeneous, with different criteria for patient selection according to the 
planned treatment intervention.   All these clinical studies had a higher proportion of women 
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than our population based study from Haugalandet (table 10a and 10b).  The majority had a 
younger mean age. With the exception of our study all were selected on the basis of histology; 
four were based only SCLC and 12 only NSCLC.  Median survival was not available in 6 
studies, one-year survival not in 10 studies and 5 year survival not in 9 studies. Three of the 
studies are retrospective of  all surgically treated patients referred to Akershus University 
Hospital (102), Haukeland University Hospital  in Bergen (105) and from Møre and Romsdal 
and Trøndelag counties in Norway (111). The five-year survival in the two last studies was 
46% and 42 % respectively, which is comparable to 52% in our study. This trend of longer 
survival in our patients may indicate a strong selection, since only 11.4% of all our patients 
were operated.  In a study from Northern Norway on patients with NSCLC recruited from 
1990 - 2004 (112) the five year survival after operation for lung cancer was as high as 57%. 
Nine of the studies were on chemotherapy, and four of these on SCLC (101, 103, 109, 113).  
In the study of Hermes the patients with performance status (PS) up to WHO 4 were also 
included (109); otherwise only patients with PS 0-2 were studied, as in the chemotherapy 
trials with NSCLC (106, 108, 118).  These various selection criteria illustrate one of the 
difficulties in comparing a population based patient cohort with cohorts selected for 
chemotherapy. Differences in patient selection are also seen in radiotherapy, where only some 
stages of NSCLC are selected in therapeutic trials (104, 107, 115).  
In one study (23) 10% were alive after 5 years, compared to 8.5% in our patient cohort. This 
was, however, a hospital based cohort and not all patients were referred to the major county 
hospital. In a national patient cohort from CRN based on 13 757 patients with advanced 
NSCLC, the median survival was 149 days for the patients included from 1994-97, and 176 
days for those from 2000-2005 (110). In our total population the median survival for stage III 
patients was 179 days and for stage IV 96 days. Again a complete comparison is difficult, 
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since we included also SCLC and those without histological confirmation of the diagnosis 
who are mostly associated with a short survival. A recent study of lung cancer patients in 
Norway from CRN indicates that survival is lower in men than in women (6). This was also 
found in the study of the operated lung cancer patients from Bergen (105).  In this study there 
were no gender differences in age, but a higher proportion of the men had been treated for 
cardiovascular disease prior to the lung cancer treatment, compared to the women. Future 
intervention studies on lung cancer must be more complete on survival including median, one 
year and five years survival. 
The prognostic factors found in our study correspond with other studies (119),  and in SCLC 
weight loss and performance status had previously been found to have prognostic  
significance both in local and extensive disease (103). Low stage has long been known to be a 
good prognostic factor after lung cancer surgery as reported in an early study which also 
included SCLC (120).  A five year relative survival of 10.9% was found in population based 
studies on lung cancer patients diagnosed in year 2000 - 2002 based on national cancer 
registries from 47 European countries, but there were marked differences between the 
countries (121). Denmark, England and Scotland have a lower five year survival rate than 
many other countries. In Denmark this has partly been explained by a less favorable stage at 
the time of diagnosis (122). For other European countries less access to specialist care is 
considered to be part of the explanation (123). Future population based studies in lung cancer 
should be done to estimate which impact the new therapeutic interventions have on survival 
of the total lung cancer population in the community. 
12.2.3 Hospitalizations and hospital days in lung cancer 
Earlier studies on costs of lung cancer care are very heterogeneous. Some include only 
insured patients (124, 125), SCLC (52, 126), NSCLC (50, 127), special treatment 
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interventions (128, 129), or the focus is only on the final part of the course of the disease (51, 
130, 131). There are also great variations on which costs are counted.  We found therefore 
that a retrospective study of hospitalization days and admissions could give us valid measures. 
Hospitalizations are regarded as a main cost driver with more than a half of the total expenses 
in cancer care (46, 49). This is in agreement for what is observed in COPD-care (132). 
In a recent retrospective study from The Netherlands  in patients with advanced NSCLC 
hospitalizations counted for most of the expenses (133). When comparing the costs after 
initial treatment between those who got only best supportive care and those who were 
additionally treated with chemotherapy, drugs represented the second largest cost driver. This 
is also confirmed in studies from France (134). We found like other studies (135, 136) that 
most resources were given to young patients with limited disease and good performance 
status. They are offered the most active treatment.  
An additional important aspect of hospitalization in lung cancer care is the time these patients 
have to spend away from their homes and families, as in our study where those with the 
shortest survival after first admission spent more than 30% of their remaining lifetime in 
institutions. Studies have shown that the majority would prefer to stay in their homes when 
given good palliative care (137). High quality palliative care at home would probably give 
those patients a higher quality of life and may reduce the expenses of hospitalizations. 
12.2.4 Terminal symptoms in lung cancer 
Terminal care is important in lung cancer with a one year mortality rate of 70% and five year 
mortality rate of about 90%. We found that altogether 99% of the lung cancer patients in our 
study had one or more symptoms in the terminal eight weeks. The most frequent was pain in 
85%, and two-third of the patients had psychological symptoms, and more than half had 
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dyspnea. When we compare with other studies (table 11) there are considerable 
inconsistencies (138-141).   
Table 11 Previous studies on symptoms in the terminal stage of lung cancer  
Author and year of 
publication 
(reference) 
Skaug 
(2007) 
(142) 
Edmonds 
(2001) 
(138) 
McCarthy 
(2000) 
(139) 
Vaino 
(1996) 
(141) 
Lutz 
(2001) 
(140) 
N 247 449 749    387         69 
Pain (%) 85 85 45 54 80 
Dyspnea (%) 54 78 70 46 92 
Nausea (%) 27 NA 10 14 NA 
Cough (%) 28 56 NA NA 90 
Hemoptysis (%) 9 NA NA NA 22 
Anxiety, insomnia, 
depression (%) 
71 60 NA 10 NA 
Dizziness, head- 
ache or paresis (%) 
28 NA Confusion      
28 
Confusion        
9 
        NA 
Time window in the 
course of the 
disease 
Terminal 
eight weeks  
 
Terminal  year  
 
0-3 terminal 
days, 3days-
1month, 1-
3months , 3–6 
months before 
death 
In the last phase 
after cancer 
treatment, but 
poorly defined 
4-6 months,     
0-3 terminal    
months 
 
Patient selection All A random 
sample of 
deaths, from 
20 districts in 
England.  
Died within 
one year.   
SCLC in        
5 hospitals  
 Referred to 
seven palliative 
centres in 
several 
countries 
69 consecutive 
patients, 
referred  to 
radiation 
oncology 
Methods  Retrospec- 
tive data 
extraction 
from 
hospital 
records 
Retrospective 
post-
bereavement 
structured 
interviews  
Prospective. 
Interviewed 2 
and 6 months. 
after inclusion, 
and survivors 
4 – 10 weeks 
after death. 
Medical 
records 
examined by  
nurses 
Prospective. 
Patient 
interview by 
nurse or 
physician. 
Excluded those 
not able to be 
interviewed 
Prospective. 
Symptom scale 
using 
interview with 
patients and  
health care      
givers  
NA: Not available 
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There is great variation between the studies in the selection of patients, methods, and 
examined time window in the course of the disease.  These differences make comparisons 
difficult and may explain the inconsistencies in the findings.   
A literature search was performed in MEDLINE on the term “lung cancer” and when 
combined with “end stage” 14 papers were found, with “terminal care” 8 papers, and in 
EMBASE combined with “terminally ill patients” 13 papers.  None of these were population 
based.  When searching on “lung cancer” and “terminal symptoms” only the present study 
was found (142).   No new studies were addressing these terms. 
Lung cancer patients have a high burden of symptoms which change over time in the course 
of the disease (143). Furthermore, these patients experience more severity and distress than 
other cancer patients (144).  To give high quality palliative treatment to lung cancer patients is 
a great challenge for health care providers, both regarding symptom control (145-148) and 
ethical issues (149). 
Quality of life has been found to be a predictor for survival in lung cancer (150, 151), and 
those who are giving care to the lung cancer patients should be aware of recent studies that 
early palliative care not only improves quality of life, but also gives prolonged survival (152, 
153).  With a median survival of less than six months focus must also be given to palliative 
care of already when lung cancer is diagnosed. 
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12.2.5 Quality of lung cancer care 
12.2.5.1 Quality indicators 
We compared four indicators on lung cancer care (staging, histology, surgery, one year 
survival) and found no differences between our local cohort from LRC and the local cohort 
from CRN and the lung cancer patients from the rest of Norway.  
There is so far no agreement  in Norway about which quality indicators to use in lung cancer 
care for all patients, all though a quality registry was established for surgically treated lung 
cancer patients from 1993-2002 (66). Since 1953, notification to CRN on every patient with 
cancer has been mandatory. The staging system used in the CRN reports was established in 
1953, and consists of three categories: localized disease, regional spread and distant 
metastasis. CRN does not get sufficient information on the staging to stage according to the 
Union for International Cancer Control (UICC) (82, 154, 155). While there is a high 
completeness regarding diagnosis, the information on treatment applied is incomplete in CRN 
since the decisions on other treatment options than surgery are not made at the time of 
reporting.  Further CRN report forms should include both UICC staging, performance status, 
more detailed information on interventions other than surgery, palliative care of the patients 
and final outcome. 
12.2.5.2 Minimal important difference 
When searching in Pub med on MID or MCID and “lung cancer” no references were found.  
In one study, however, on the Functional Assessment of Cancer Therapy – Lung (FACT-L) 
measuring the quality of life in a 7-item scale, an increase in the score of 2 point was found 
meaningful when the patient improved, and reduction of  2.75 when the patient worsened 
(74).  
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Various methods are used to estimate the minimal important difference (MID) in an outcome 
measure, giving sufficient benefit for the patient to change the management of the disease. 
Some use the expression minimal clinical important difference (MCID) (69, 73). One method 
is to make an estimate of MID based on patients’ preference. This has been done when 
measuring health status in pulmonary rehabilitation in COPD, either by asking about the 
judgment of the patient before and after intervention (73) or the judgment  relative to a group 
of other patients (156). Another method in estimating MID is to use expert judgments to 
assess which size in differences in health status as in COPD are of importance (157). There 
was good agreement between these two methods (73).  A third way to calculate the MID is 
the anchor-based method. A well established test with known MID is the reference, and the 
MID in the test of interest may be calculated via logistic regression analysis (158). A linear 
relationship between these two tests is required.  A fourth method is the distribution-based 
estimate of MID based on statistical calculations without judgment from patients or experts 
(159), which is also discussed in ERS/ATS statement on outcomes for COPD in 
pharmacological trials (160). In a recent study the MID in severe COPD after lung volume 
surgery patient outcome measure (6 minute walking distance) was determined using the 
anchor based method (158).  The value of MID may however be different in different 
interventions as lung volume surgery, pulmonary rehabilitation or pharmacological treatment 
in COPD patients, or in patient groups with different degree of serious disease. Furthermore, 
MID obtained at a group level may not be appropriate to judge the improvement of the 
individual patient (161).  
We attempted to find the MID for four outcome measures by the use of the expert-preference 
method (chapter 10.12.2).  The thoracic physicians estimated MID in deviation in relative 
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percent from the national average of about 20% as sufficient to make an impact on their 
management of lung cancer (paper 4 and appendix 17.3, 17.4, 17.5).  
To get a sufficient number obtaining a relative change of 20% with a power of 80% we would 
need a sample size to estimate the quality which is much higher than the number of incident 
lung cancer patients observed in our hospital area in five years. We concluded that it is 
difficult within a reasonable time to get good estimates of the quality of lung cancer care in a 
hospital with 40 incident lung cancer patients per year. 
 A model to overcome this problem and use the quality indicators from CRN is to merge 
hospitals within a health region to a larger unit with standardized routines for diagnosis and 
treatment of lung cancer. To a certain degree this is done in Norway, since lung cancer 
surgery now is centralized to six university hospitals, but little standardizations are done so far 
for palliative care. In Denmark, a report on an indicator project on lung cancer indicated  a 
better quality on lung cancer surgery in hospitals with more than 170 new cases yearly (162), 
and in a recent article from Germany it was suggested that a center treating lung cancer 
should have at least 200 new cases per year (14).  
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13.  Main conclusions  
1a.The age-adjusted yearly incidence rate of lung cancer in Haugalandet was 39.9 per 100000 
in men and 10.8 per 100 000 in women.  
1b.The long term survival in the whole population of lung cancer patients is poor, with a five-
year survival of 8.5% and median survival time of 5.7 months. Young age, limited disease, 
good performance status and no weight loss were predictors for longer survival, which was 
not influenced by the diagnostic delay time. 
2. The 271 incident lung cancer patients in the Haugalandet area 1990-96 had a median of      
three admissions and 35 hospital days, and most was spent on those surgically treated. For 
those 253 patients who died before December 1st, 2003, 19% of their survival time was spent 
in health institutions. 
3. A very high proportion of the lung cancer patients have symptoms requiring treatment in 
the terminal stage, and pain, dyspnea and psychological symptoms were the most frequent.  
Nausea is more present in SCLC, and nausea and dyspnea are more frequent when the disease 
is extensive at diagnosis. Younger patients have more often psychological symptoms than 
patients older than 65 years.  Health care workers giving palliative treatment should be aware 
of these predictors. 
4. No differences were found of the quality indicators available in CRN when comparing the 
lung cancer care at Haugalandet with the rest of the Norwegian population.   However, to get 
sufficient sample sizes to detect a 20% different estimate from the national average in quality 
indicators, smaller management units need to merge into network with standardized programs 
for diagnosis and curative and palliative treatment of lung cancer.  A national lung cancer 
quality registry would be favorable. 
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14. Future perspectives 
 
The last patients included in our retrospective study were diagnosed with their lung cancer at 
the end of 1996. At that time the use of chemotherapy in advanced NSCLC was not routinely 
established, even if studies were ongoing, and the role of  neoadjuvant chemotherapy after 
surgery for stage 2 disease was not yet clarified (163).  The value of lung cancer surgery was 
questioned (164).  Considering the importance of lung cancer as cause of mortality, the 
disease had  received too little attention (165). 
Since 1996 there have been marked changes in the management of lung cancer (166). The 
Norwegian Lung Cancer Group has published guidelines for diagnosis and treatment (167). 
Important changes are the extensive use of chemotherapy in NSCLC and positron emission 
tomography before potential surgical treatment. 
14.1 Consequences of our observations 
14.1.1 Clinical issues 
Centralizing of lung cancer patients eligible for radical treatment should continue. Thus it 
seems appropriate that lung cancer surgery is concentrated to only six university hospitals in 
Norway and radiation therapy to seven hospitals.  Palliative chemotherapy should be given as 
far as possible locally in order to keep the patient near to home and family as much as 
possible in the remaining life time. In spite of new treatment options, it remains to estimate 
how this will improve the long term survival for the whole community population of lung 
cancer.   
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14.1.2 Research issues 
This study forms a base for further comparative studies. In spite of  increased emphasis in the 
treatment of NSCLC the last 15 years it remains to observe which impact with regard to 
survival and quality of life this has on the whole population of lung cancer patients in the 
community. A new study of the population from the same geographical area may provide 
answers on that question, in addition also to show if the manifestations of the patients has 
changed lately, as well as the management. A prerequisite for future community studies is 
however a more valid registration of all intervention procedures, records of all outpatients 
visits and quality of life.    
Further studies should be performed on costs of lung cancer, including direct as well as 
indirect costs, in the community.  Such studies should also include the procedures on 
diagnosis and treatment of lung cancer done by the primary health care. 
Future research questions could be: 
1. What is the optimal individual management of lung cancer in a local hospital area? 
2. What is the most effective use of a multidisciplinary team for lung cancer? 
3. What is the value of investigations of molecular-genetic markers for the treatment of 
lung cancer? 
4. What is the effect of different palliative lung cancer treatments on quality of life and 
health economy in a general population? 
5. What lung cancer patients are invited to participate in controlled clinical trials?  
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